Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers (NCT03564340)
A Phase 1/2 Study of REGN4018 (Ubamatamab), a MUC16×CD3 Bispecific Antibody, Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers
🩺 Plain-English Summary (8th-Grade Level)
The main purpose of this study is to: * Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus * The study will also look at the levels of ubamatamab and/or cemiplimab in the body and measure how well the body can remove the study drug(s). This is called pharmacokinetics * The study will also look at any signs that ubamatamab alone or with cemiplimab can treat recurrent advanced ovarian cancer or cancer of the uterus * To find out how safe and tolerable pretreatment is in combination with ubamatamab and to see how well it works to prevent or minimize Cytokine Release Syndrome (CRS)
Who can join: Review the eligibility criteria below.
Location: University of Alabama_6th Ave — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (52 Sites)
Showing the first 25 of 52 sites.
- University of Alabama_6th Ave — Birmingham, Alabama
- Massachusetts General Hospital — Boston, Massachusetts
- Dana Farber / Harvard Cancer Center — Boston, Massachusetts
- Mayo Clinic - Rochester — Rochester, Minnesota
- Roswell Park Cancer Institute — Buffalo, New York
- Columbia University Medical Center — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- The Ohio State University Wexner Medical Center — Columbus, Ohio
- Stephenson Cancer Center — Oklahoma City, Oklahoma
- Sarah Cannon Research Institute — Nashville, Tennessee
- Virginia Commonwealth University — Richmond, Virginia
- Prince of Wales Hospital — Randwick, New South Wales
- Peter MacCallum Cancer Center — Melbourne,
- Universitair Ziekenhuis Antwerpen — Edegem, Antwerp
- Grand Hopital de Charleroi — Charleroi, Hainaut
- UZLeuven — Leuven, Vlaams-Brabant
- Hopital Lyon Sud — Pierre-Bénite, Auvergne-Rhône
- Centre Georges Francois Leclerc — Dijon, Bourgogne-Franche-Comté
- Institut Bergonie — Bordeaux, New Aquitaine
- Centre Francois Baclesse (CFB) — Caen, Normandy
- Centre Antoine Lacassagne — Nice, Provence Alpes Cote dAzur
- Institut Gustave Roussy — Villejuif, Île-de-France Region
- Rambam Health Care Campus — Haifa,
- Sharet Institute of Oncology — Jerusalem,
- Sheba Medical Center — Tel Litwinsky,
📞 Contact the Study Coordinator
Phone: (844) 734-6643
Email: clinicaltrials@regeneron.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Recurrent Ovarian Cancer
- A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. — Durham, North Carolina
- Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer — Toronto, Ontario
- A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression — Los Angeles, California
- Investigating Participation Patterns Among Recurrent Ovarian Cancer Patients — San Francisco, California
- CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer — Pittsburgh, Pennsylvania
Explore by condition: All Recurrent Ovarian Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.